Benzinga
Benzinga
Noticias de España
Acciones
Índices
Bonos
ETFs
Economía
General
Noticias de EE.UU.
Acciones
Índices
Ganancias
Economía
Mercados de predicción
Mercados privados
Otros mercados
Calificaciones de analistas
Trading
Comunicados de prensa
Noticias Mundiales
Europa
Asia
Latinoamérica
Criptomonedas
Noticias
Altcoins
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Formación
Invertir en criptomonedas
Invertir en acciones
Forex
Benzinga
martes, octubre 27
Noticias de España
Acciones
Índices
Bonos
ETFs
Economía
General
Noticias de EE.UU.
Acciones
Índices
Ganancias
Economía
Mercados de predicción
Mercados privados
Otros mercados
Calificaciones de analistas
Trading
Comunicados de prensa
Noticias Mundiales
Europa
Asia
Latinoamérica
Criptomonedas
Noticias
Altcoins
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Formación
Invertir en criptomonedas
Invertir en acciones
Forex
AstraZeneca PLC
AZN
NYSE
Lista de seguimiento
Get Report
Trade with Public
Get Report
Trade with Public
$172.06
0.57
0.33%
Últ. Act.: Oct 27, 8:12 AM
Get Report
Panorámica general
Noticias
Previsión de beneficios
Eventos
Precios objetivo
Finanzas
Sentimiento
Propiedad
Dividendos
Comparar
Opciones
Informe de acciones
Ganancias:
Beneficios de Q3 2026 dentro de 3 días de ahora en vie oct 30th, antes de la apertura del mercado
Conferencia telefónica:
Conferencia telefónica programada para dentro de 3 días a las 10:30 a. m.
Haz clic para ver el webcast
AstraZeneca Financials
AstraZeneca (AZN) financial statements — income, revenue, gross margin and key metrics.
Earnings & Guidance News
Alnylam Lowers 2026 Outlook As Second-Line Amvuttra Demand Normalizes, Stock Tanks
Alnylam cut its 2026 sales outlook despite a Q2 earnings beat as slower ATTR-CM market growth weighed on expectations and investors reacted.
Vandana Singh
Dow Gains Over 250 Points Amid Lower Oil Prices: Investor Sentiment Weakens, Greed Index Remains In ‘Fear’ Zone
U.S. stocks mixed as Dow gains 250 points amid decline in oil prices. CNN Money Fear and Greed Index shows market sentiment in Fear zone.
Avi Kapoor
Pipeline Speed Bump Doesn't Shake AstraZeneca's $80 Billion Revenue Ambition
AstraZeneca (AZN) Q2 2026: EPS beats estimates at $2.63 despite missing revenue targets. Oncology sales up 16%. Get the full recap.
Vandana Singh
PRO
AstraZeneca Reconfirms FY2026 Guidance, Expecting Mid-To-High Single-Digit Revenue Growth And Low Double-Digit Core EPS Growth At Constant Exchange Rates
Benzinga Newsdesk
PRO
AstraZeneca Q2 Adj. EPS $2.63 Beats $2.48 Estimate, Sales $15.384B Miss $15.459B Estimate
AstraZeneca (NASDAQ:AZN) reported quarterly earnings of $2.63 per share which beat the analyst consensus estimate of $2.48 by 6.05 percent. This is a 141.28 percent increase over earnings of $1.08 per share from the
Benzinga Newsdesk
Tempus AI's Big Pharma AI Partnerships Are Getting Bigger And Stickier
Tempus AI (TEM) Q1 results: Revenue up 36.1% to $348.1M, beating estimates. TEM raises 2026 outlook amid strong AI & diagnostic demand.
Lekha Gupta
